Atlas Trials

Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

Clinical trial NCT07369791 · WITHDRAWN

Trial details

NCT number
NCT07369791
Sponsor
National Health Research Institutes, Taiwan
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Biliary Tract Cancer(BTC)
Start date
2026-12-01
Primary completion
2035-12-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.